TriCos Biotherapeutics proprietary single-chain TNFSF-ligand technology mimics the endogenous TNFSF ligands and clearly differentiates from competitor approaches in the field of immuno-oncology. The single-chain TNFSF-technology was used to construct potent systemic hexavalent - and tumor-targeted bispecific co-stimulatory T cell agonists, with a focus on the CD27 axis. CD27 is constitutively expressed by a majority of T cells and is a key co-stimulatory pathway to expand and sustain T cell activity.